Results 41 to 50 of about 1,130 (117)
Background PDGFRA genetic alterations are a well-established oncogenic driver in gliomas. However, targeted monotherapy against PDGFRA such as avapritinib has achieved limited clinical efficacy, and the mechanism underlying avapritinib resistance remains
Han Xie +9 more
doaj +1 more source
Two new thiophene–pyrazole derivatives, 8a and 8b, were synthesized from thiophene 3 precursor and fully characterized. The structure of 8a was confirmed by single‐crystal X‐ray diffraction, which revealed a nonplanar conformation stabilized by NH···O hydrogen bonding and weak intermolecular contacts.
Abdullatif Bin Muhsinah +3 more
wiley +1 more source
In the field of rare diseases—where traditional clinical trials are often impractical—real‐world data (RWD) have emerged as a scientifically valid alternative to support regulatory decision making. This study systematically evaluates the utilization of RWD in orphan drug approvals by the FDA Center for Drug Evaluation and Research (CDER) over the past ...
Minji Kim, Eunjin Hong
wiley +1 more source
Targeting Tumor Stroma: Current Challenges and Future Directions
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang +7 more
wiley +1 more source
Post‐translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases
Posttranslational modifications (PTMs) serve as rapid and reversible molecular switches that reshape protein activity, stability, and interactomes, thereby governing virtually all physiological cues ranging from signal transduction to epigenetic memory. Mass spectrometry‐based proteomics has substantially expanded our understanding of PTM emergence and
Shuning Zhang +3 more
wiley +1 more source
Enhanced PIEZO1 expression in mast cells of mastocytosis skin lesions: Relevance to Darier's sign
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page e598-e601, July 2026.
Yoshiaki Kobayashi +9 more
wiley +1 more source
Discovery of Lomitapide as a Novel Mast Cell Regulatory Agent Through Chemical Library Screening
Chemical library screening identified lomitapide as a novel mast cell (MC) regulatory agent. Lomitapide selectively inhibits IgE/Ag‐ or phorbol 12‐myristate 13‐acetate (PMA)/ionomycin‐mediated MC degranulation by altering plasma membrane dynamics, including endocytosis and membrane fusion. ABSTRACT Allergic diseases are a global health concern, and new
Shiori Mamorita +3 more
wiley +1 more source
Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA
Avapritinib is the only potent and selective inhibitor approved for the treatment of D842V-mutant gastrointestinal stromal tumors (GIST), the most common primary mutation of the platelet-derived growth factor receptor α (PDGFRA).
A. Teuber +13 more
doaj +1 more source
Tissue‐Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts
ABSTRACT Although all myeloid cells are considered to derive from hematopoietic stem cells, the cells in each myeloid lineage are heterogeneous populations, and their distribution and functions vary, depending on underlying physiologic and pathologic processes, age, sex, and genetic and epigenetic signatures.
Peter Valent +27 more
wiley +1 more source
ABSTRACT Introduction Gastrointestinal stromal tumors (GISTs) originate from mesenchymal precursor cells of the gastrointestinal wall and account for approximately 3% of all gastrointestinal malignancies. In adults, these tumors most commonly harbor mutually exclusive activating mutations in KIT, PDGFRA, BRAF, or SDH‐family genes.
Maria Grazia Rodriquenz +14 more
wiley +1 more source

